Inve US ▾
ININSM

What INSMED promised, and what happened

Guidance Tracker · every commitment management made on a call, tracked from the quarter it was made

Guidance

What management said, and what became of it

14 of 16 judged targets kept · 13 open · verdicts reflect calls analysed to Jun 2026.

TargetOriginal wordingSaidLatest callVerdict
Next-generation DPP1 (INS1033) first candidate clinic entryEnter the clinic in 2026Mar 2025Jun 2026:The FDA recently cleared the IND for INS1033, the first of several next-generation DPP1 inhibitors advancing within our pipeline to proceed into the clinic.
Call transcript, Jun 2026 · no direct link		Achieved
Brensocatib HS (CEDAR) Phase II full topline readout (all 214 patients)Topline readout in first half of 2026Sep 2025No later analysed call mentions it.Pending
Brensocatib approvals and launches in Europe, UK and JapanApprovals and launches in each region in 2026Mar 2025Jun 2026:I think there is a very good reason to believe that Japan is going to deliver, starting next year.
Call transcript, Jun 2026 · no direct link		Delayed

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

The full ledger

Open INSMED’s full ledger

A free account opens 5 company ledgers a month. All 29 tracked commitments, with each call’s wording and source.

US Pro opens 100 a month, first month free →

The rest of the ledger

Pro opens all 29 tracked commitments for INSMED

Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

Upgrade to Pro, one month free